Pet Cancer Therapeutics Market Outlook

The global pet cancer therapeutics market size is set to reach US$ 405.90 billion in 2023. Overall sales of pet cancer therapeutics are likely to surge at 10% CAGR, taking the forecasted market valuation to US$ 1052.80 billion by the end of 2033.

Alternative therapies, such as acupuncture, herbal remedies, and dietary supplements, are becoming increasingly accepted as a means of alleviating some of the discomfort associated with conventional cancer treatments and enhancing the health of pets as a whole. These treatments are not meant to be used in place of standard care, but they can provide comfort and assistance during chemotherapy for pets.

Precision medicine, or personalised medicine, is the practise of customising medical care to each patient by taking into account their unique genetic makeup and molecular profile. As scientists learn more about the genetic mutations that cause various canine and feline cancers, this method is gaining prominence in the field. If veterinarians can pinpoint these mutations, they can create targeted therapies that outperform standard chemotherapy.

Developed nations like the United States and Europe have seen the greatest increases in the number of people keeping pets as companions. More pet owners are willing to spend money on treatments to ensure their pets' health and happiness, increasing demand for pet cancer therapeutics.

Technology advancements have facilitated the detection and treatment of cancer in pets. PET/CT scans, for example, are helping veterinarians diagnose cancer more precisely, and developments in surgery and anaesthesia have made it easier and safer to operate on pets with the disease. This is improving pet survival rates and making it easier for pet owners to afford cancer treatment.

New drugs and treatment methods are being developed thanks to the increased focus on pet cancer research. The rising incidence of cancer in pets is one factor, but technological advancements are also facilitating research into the disease. Gene sequencing has been instrumental in the discovery of the genetic mutations that underlie various forms of cancer, thereby paving the way for the development of targeted therapies.

Attributes Details
Pet Cancer Therapeutics Market CAGR (2023 to 2033) 10%
Pet Cancer Therapeutics Market Size (2023) US$ 405.90 billion
Pet Cancer Therapeutics Market Size (2033) US$ 1052.80 billion

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Pet Cancer Therapeutics Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

According to recent research by Future Market Insights, the pet cancer therapeutics market is projected to expand at a rate of 10% during the forecast period from 2023 to 2033. The market outlook could be divided into short term, medium term and long term.

Short term (2023 to 2025): Many pet owners are prepared to pay more than ever before for their pets' medical care. More and more people are spending money on cancer treatments for their pets, and this is a major factor in the expansion of the pet cancer therapeutics market. Since pets are increasingly considered members of the family, their owners are willing to invest large sums of money into their care.

Medium term (2025 to 2028): Cancer in pets is a growing concern for pet owners as they learn more about preventative care. This realisation has increased the demand for cancer screenings and treatments that aim to identify the disease at an early stage. Many pet owners now include annual checkups, diagnostic testing, and cancer screening as part of their routine care because early detection is key to successful treatment.

Long term (2028 to 2033): Improvements in veterinary medicine and the prevalence of preventative care have led to the increased longevity of domesticated animals. However, the likelihood of contracting cancer rises with chronological age. Demand for cancer treatments that can extend the lives of pets while keeping their quality of life intact is rising as a result of this trend. The need for efficient cancer treatments is growing as pet lifespans rise along with the prevalence of cancer.

Comparative Adjacent Table

Pet Cancer Therapeutics Market:

Attributes Pet Cancer Therapeutics Market
CAGR (2023 to 2033) 10%
Market Value (2026) US$ 1052.80 billion
Growth Factor Rise in the prevalence of pet cancer
Opportunity Rapid increase in funding for cancer therapy research activities
Restraints Lack of veterinary oncologists

Cancer Supportive Care Drugs Market:

Attributes Cancer Supportive Care Drugs Market
CAGR (2023 to 2033) 2.2%
Market Value (2026) US$ 26053.36 million
Growth Factor Rising geriatric population, which is more susceptible to cancer
Opportunity Growing focus on personalized medicine and targeted therapies
Restraints Side effects associated with these drugs, which may lead to reduced patient compliance

Veterinary Oncology Market:

Attributes Veterinary Oncology Market
CAGR (2023 to 2033) 12.1%
Market Value (2026) US$ 812.88 million
Growth Factor Growing demand for pet insurance and healthcare services
Opportunity Development of novel and targeted therapies for animal cancer treatment
Restraints Limited availability of specialized veterinary oncologists
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the drivers in the market?

The rapid uptake of cutting-edge, novel medicines for pet care is driving growth in the pet cancer therapeutics market. The global market is being propelled by the fact that more and more people are able to afford to get pets, particularly dogs and cats. The rising incidence of cancer in pets is driving up the demand for therapeutics to treat the disease, and pet owners are responding by spending more money on their animals' health. There will be new products on the market in the coming years as a result of manufacturers' heavy investment in R&D to develop new treatments for pet cancer. Market dominators with a wide selection of products will increase their share of the industry by producing ground-breaking medicines. The market could expand more quickly if more people knew about the dangers of pet cancer drugs and other illnesses. The high price of cancer therapeutics for pets is also likely to be a problem, especially in less developed regions of the world.

What is restraining the market growth?

The potential severity of adverse effects from some cancer therapeutics for pets is a major deterrent to owners seeking care for their animals. Animals undergoing chemotherapy, for instance, often experience gastrointestinal distress and hair loss. Radiation therapy has similar side effects, including skin irritation and tiredness. These negative effects can discourage pet owners from pursuing treatment and lower the quality of life for their pets.

The importance of early detection and treatment for canine and feline cancers is not widely known among pet owners. As a result, pets with cancer may not receive timely treatment, which can lessen the effectiveness of that treatment and worsen their prognoses.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

What are the challenges that the market is facing?

The high cost of cancer therapeutics for pets is a major deterrent for some owners. This is especially true in less developed regions, where pet owners may not have ready access to veterinary care of the highest standard.

Although there have been great strides in the treatment of cancer in pets in recent years, there are still some types of cancer for which there are few options. This can make effective treatment for some pets with cancer more challenging to provide.

Some pet owners may opt for less conventional cancer therapies, such as acupuncture or herbal medicine, for their pets. These treatments may be more affordable, but they aren't always supported by science and may not be effective against pet cancer.

Regional Analysis

What is driving the United States Pet Cancer Therapeutics Market?

More people than ever before are keeping pets as companions, and this trend can be seen all over the world. Over 67% of American households currently have a pet, according to the American Pet Products Association, continuing a trend of rising pet ownership over the past three decades. The need for veterinary services, such as cancer treatment, is rising in tandem with the pet population. As a result, the market for pet cancer therapeutics is expanding as more and more people look for novel and effective therapies for their pets.

How is the Indian Pet Cancer Therapeutics Market expected to grow during the forecast period?

During the predicted time period, the market for cancer therapeutics for pets in India is projected to expand at a healthy rate. The growth of the market in India is anticipated to be driven by factors such as the increasing adoption rate of pets, increased awareness of pet healthcare, and rising expenditure on pet healthcare. The availability of cutting-edge cancer treatments for pets and the proliferation of veterinary hospitals and clinics across the country are also factors that will drive demand.

Reports estimate that between 2021 and 2026, the Indian market for pet cancer therapeutics will increase from its 2020 valuation of about USD 17.8 million by a compound annual growth rate (CAGR) of about 9.5%. The rising incidence of pet cancer and the subsequent demand for efficient cancer treatments are major factors driving the market.

Furthermore, the Indian government has launched various pet health insurance schemes and increased public awareness campaigns to promote pet healthcare and welfare. As a result of these actions, the pet cancer therapeutics market in India is expected to expand.

What is the Japanese Pet Cancer Therapeutics Market Outlook?

According to market research, the value of the Japanese pet cancer therapeutics market was around USD 25 million in 2020, and it is expected to grow at a CAGR of around 8% between 2021 and 2026. The availability of novel therapeutics and the rising demand for cutting-edge cancer treatments for pets are driving the market forward.

However, the market expansion may be stymied by the high price of pet cancer treatments and the scarcity of effective treatments for some types of pet cancer. It will be crucial for the future development of the Japanese pet cancer therapeutics market to address these issues and increase access to effective pet cancer therapeutics.

Category Wise Insights

The market for oral pet cancer therapeutics is expected to be worth more than US$ 359 million by 2032. Growth in this market segment is being bolstered by the significant advances in oral medicines because of the clinical benefits they offer, such as the convenience and comfort of home therapy and fewer clinic visits. The first oral chemotherapy pill for dogs with lymphoma, Laverdia-CA1 (also known as Verdinexor), was conditionally approved by the FDA in May 2022. These capsules can enhance chemotherapeutic agents' ability to inhibit cancer cell proliferation by inducing apoptosis.

The dog species segment of the pet cancer therapeutics market is expected to be worth over US$ 352 million by 2022 as a result of increasing penetration and a rise in the occurrences of feline cancer. Additionally, risk factors associated with in-breeding and mixed-breed dogs have increased the likelihood of tumours and lymph. In a recent study from 2022, the researchers found that the increased longevity of dogs was a major factor in the detection of cancer at an early stage. This increase was attributed to natural selection favouring the survival of pets that were kept in sterile environments and given access to better medical care. According to the study's findings, the global cancer rate has risen in tandem with the ageing dog population.

Competitive Landscape

Zoetis Inc., Merial Inc., Elanco Animal Health, Anivive Lifesciences, Qbiotics, AB Science, NovaVive, and ELIAS Animal Health are just some of the major players in the market for cancer therapeutics for pets. To stay ahead of the competition, these companies are investing in research and development programmes for brand new products. For instance, in June of 2022, Boehringer Ingelheim, a biopharmaceutical company, and CarthroniX, a developer of small molecule-based therapies for ageing-related and degenerative diseases, announced a collaboration to advance the field of canine oncology through the discovery and development of novel small molecule therapeutics. This new approach to canine cancer treatment is likely to aid Boehringer Ingelheim in expanding its Animal Health division.

Key Segments

Pet Cancer Therapeutics Industry by Therapy:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Combination Therapy

Pet Cancer Therapeutics Industry by Route of Administration:

  • Oral
  • Injection

Pet Cancer Therapeutics Industry by Species:

  • Dogs
  • Cats

Pet Cancer Therapeutics Industry by Application:

  • Lymphoma
  • Mast Cell Cancer
  • Melanoma
  • Mammary and Squamous Cell Cancer
  • Others

Pet Cancer Therapeutics Industry by Geography:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania

Frequently Asked Questions

Why is the United States Market Witnessing Higher Growth?

The rising generic populations are fueling the demand in the United States.

Why is Sales of Pet Cancer Therapeutics Surging in Europe?

The growing focus on medicine and targeted therapies in Europe has increased the demand.

What is Driving the Adoption of Pet Cancer Therapeutics Globally?

Healthcare experts have necessitated pet cancer therapeutics adoption.

What is the Contribution of the United States in the Market?

The United States hold a share of 67% of the global market in 2023.

Which Region Presents Lucrative Growth Opportunities?

North America to witness lucrative growth opportunities through 2033.

Table of Content

1. Executive Summary | Pet Cancer Therapeutics Market 

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2022 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Therapy

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2022 to 2033

        5.3.1. Chemotherapy

        5.3.2. Immunotherapy

        5.3.3. Targeted Therapy

        5.3.4. Combination Therapy

    5.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Therapy, 2022 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2033

        6.3.1. Oral

        6.3.2. Injection

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Pet

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Pet , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Pet , 2022 to 2033

        7.3.1. Dogs

        7.3.2. Cats

    7.4. Y-o-Y Growth Trend Analysis By Pet , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Pet , 2022 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Application

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2022 to 2033

        8.3.1. Lymphoma Cancer

        8.3.2. Mast Cell Cancer

        8.3.3. Melanoma Cancer

        8.3.4. Mammary Cancer

        8.3.5. Squamous Cell Cancer

    8.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Application, 2022 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. South Asia

        9.3.5. East Asia

        9.3.6. Oceania

        9.3.7. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033

        10.2.1. By Country

            10.2.1.1. The USA

            10.2.1.2. Canada

        10.2.2. By Therapy

        10.2.3. By Route of Administration

        10.2.4. By Pet

        10.2.5. By Application

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy

        10.3.3. By Route of Administration

        10.3.4. By Pet

        10.3.5. By Application

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Therapy

        11.2.3. By Route of Administration

        11.2.4. By Pet

        11.2.5. By Application

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy

        11.3.3. By Route of Administration

        11.3.4. By Pet

        11.3.5. By Application

    11.4. Key Takeaways

12. Europe Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. United Kingdom

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Therapy

        12.2.3. By Route of Administration

        12.2.4. By Pet

        12.2.5. By Application

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy

        12.3.3. By Route of Administration

        12.3.4. By Pet

        12.3.5. By Application

    12.4. Key Takeaways

13. South Asia Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Rest of South Asia

        13.2.2. By Therapy

        13.2.3. By Route of Administration

        13.2.4. By Pet

        13.2.5. By Application

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapy

        13.3.3. By Route of Administration

        13.3.4. By Pet

        13.3.5. By Application

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Therapy

        14.2.3. By Route of Administration

        14.2.4. By Pet

        14.2.5. By Application

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Therapy

        14.3.3. By Route of Administration

        14.3.4. By Pet

        14.3.5. By Application

    14.4. Key Takeaways

15. Oceania Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033

        15.2.1. By Country

            15.2.1.1. Australia

            15.2.1.2. New Zealand

        15.2.2. By Therapy

        15.2.3. By Route of Administration

        15.2.4. By Pet

        15.2.5. By Application

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Therapy

        15.3.3. By Route of Administration

        15.3.4. By Pet

        15.3.5. By Application

    15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2022 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Therapy

        16.2.3. By Route of Administration

        16.2.4. By Pet

        16.2.5. By Application

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Therapy

        16.3.3. By Route of Administration

        16.3.4. By Pet

        16.3.5. By Application

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Therapy

            17.1.2.2. By Route of Administration

            17.1.2.3. By Pet

            17.1.2.4. By Application

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Therapy

            17.2.2.2. By Route of Administration

            17.2.2.3. By Pet

            17.2.2.4. By Application

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Therapy

            17.3.2.2. By Route of Administration

            17.3.2.3. By Pet

            17.3.2.4. By Application

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Therapy

            17.4.2.2. By Route of Administration

            17.4.2.3. By Pet

            17.4.2.4. By Application

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Therapy

            17.5.2.2. By Route of Administration

            17.5.2.3. By Pet

            17.5.2.4. By Application

    17.6. United Kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Therapy

            17.6.2.2. By Route of Administration

            17.6.2.3. By Pet

            17.6.2.4. By Application

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Therapy

            17.7.2.2. By Route of Administration

            17.7.2.3. By Pet

            17.7.2.4. By Application

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Therapy

            17.8.2.2. By Route of Administration

            17.8.2.3. By Pet

            17.8.2.4. By Application

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Therapy

            17.9.2.2. By Route of Administration

            17.9.2.3. By Pet

            17.9.2.4. By Application

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Therapy

            17.10.2.2. By Route of Administration

            17.10.2.3. By Pet

            17.10.2.4. By Application

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Therapy

            17.11.2.2. By Route of Administration

            17.11.2.3. By Pet

            17.11.2.4. By Application

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Therapy

            17.12.2.2. By Route of Administration

            17.12.2.3. By Pet

            17.12.2.4. By Application

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Therapy

            17.13.2.2. By Route of Administration

            17.13.2.3. By Pet

            17.13.2.4. By Application

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Therapy

            17.14.2.2. By Route of Administration

            17.14.2.3. By Pet

            17.14.2.4. By Application

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Therapy

            17.15.2.2. By Route of Administration

            17.15.2.3. By Pet

            17.15.2.4. By Application

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Therapy

            17.16.2.2. By Route of Administration

            17.16.2.3. By Pet

            17.16.2.4. By Application

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Therapy

            17.17.2.2. By Route of Administration

            17.17.2.3. By Pet

            17.17.2.4. By Application

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Therapy

            17.18.2.2. By Route of Administration

            17.18.2.3. By Pet

            17.18.2.4. By Application

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Therapy

            17.19.2.2. By Route of Administration

            17.19.2.3. By Pet

            17.19.2.4. By Application

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Therapy

            17.20.2.2. By Route of Administration

            17.20.2.3. By Pet

            17.20.2.4. By Application

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Therapy

            17.21.2.2. By Route of Administration

            17.21.2.3. By Pet

            17.21.2.4. By Application

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Therapy

        18.3.3. By Route of Administration

        18.3.4. By Pet

        18.3.5. By Application

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Zoetis, Inc.

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Elanco Animal Health

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Boehringer Ingelheim International GmbH

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Dechra Pharmaceuticals

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. AB Science

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Qbiotics

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. NovaVive, Inc.

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. ELIAS Animal Health

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Karyopharm Therapeutics, Inc.

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Torigen Pharmaceuticals Inc.

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Cancer Diagnostics Market

March 2021

REP-GB-1090

August 2023

315 pages

Services and Utilities

Southeast Asia Pet Care Market

December 2014

REP-GB-45

111 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Pet Cancer Therapeutics Market